儿童毛发疾病低剂量口服米诺地尔应用的国际共识声明
该国际共识采用改良Delphi流程,针对12岁以下毛发疾病患儿使用低剂量口服米诺地尔(LDOM)的患者选择、剂量、安全性和监测形成推荐。51名专家中49人完成三轮调查,127个初始条目中84个达成共识,支持LDOM用于毛发微小化、毛周期异常等,并给出固定体重和mg/kg两种剂量策略。
要点
- LDOM支持用于4至<12岁患儿毛发微小化、毛周期异常及毛干疾病。
- 固定剂量按体重分层:<20 kg 0.250-0.625 mg,20-40 kg 1.250 mg,>40 kg 1.875 mg。
- 起始0.01-0.02 mg/kg/d为灵活替代,剂量可上调50%-100%,每3-6月复评。
核心结论
- 该共识为12岁以下毛发疾病患儿使用LDOM提供了结构化的儿科专用框架,支持其作为灵活的非免疫抑制治疗策略。
研究设计与样本
- 采用改良Delphi流程,2025年6月30日至2026年3月7日进行三轮迭代调查,98名临床医生完成预筛,51名符合条件(治疗过>10例儿科LDOM患者)受邀。
- 50名来自9个国家的专家完成第1、2轮,49名(98.0%保留率)完成第3轮,共识定义为5点Likert量表上≥70%同意。
主要发现
- 127个初始条目中84个达成共识。
- LDOM支持用于4至<12岁患儿的毛发微小化(100%)、毛周期异常(100%)、毛干疾病(84%),以及特定瘢痕性脱发的辅助治疗(98%)。
- 偏好LDOM而非外用米诺地尔的原因包括操作困难、耐受性差、疗效不足、照护者偏好、弥漫性脱发、感觉敏感或宠物中毒风险(74%-96%)。
- 固定体重剂量与mg/kg剂量策略均达成共识:固定剂量为<20 kg 0.250-0.625 mg、20-40 kg 1.250 mg、>40 kg 1.875 mg(80%);起始0.01-0.02 mg/kg/d(73.5%)为灵活替代。
- 剂量上调50%-100%及每3-6个月复评达成共识;禁忌证包括心包积液或填塞及嗜铬细胞瘤。
关键数值与推荐
- 共识阈值:5点Likert量表上≥70%同意。
- 固定剂量:体重<20 kg为0.250-0.625 mg;20-40 kg为1.250 mg;>40 kg为1.875 mg(80%同意)。
- 起始剂量0.01-0.02 mg/kg/d(73.5%同意);剂量上调50%-100%,每3-6个月复评。
- 低风险患者不普遍需要常规基线检测和血压监测。
临床怎么用
- 对4至<12岁毛发微小化、毛周期异常或毛干疾病患儿,可考虑LDOM,尤其当外用米诺地尔存在操作困难、耐受性差或疗效不足时。
- 可根据体重选择固定剂量或按0.01-0.02 mg/kg/d起始,剂量上调50%-100%,每3-6个月复评。
- 低风险患者无需常规基线检测和血压监测;禁忌证包括心包积液或填塞及嗜铬细胞瘤。
- LDOM可作为长期治疗并支持逐渐减量策略,也可与螺内酯、糖皮质激素、JAK抑制剂等联合使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Low-dose oral minoxidil (LDOM) is increasingly used off-label to treat pediatric hair disorders; however, standardized guidance for patient selection, dosing, safety, and monitoring in patients younger than 12 years is lacking. OBJECTIVE: To establish expert consensus recommendations for LDOM use in pediatric patients (age <12 years) with hair disorders. EVIDENCE REVIEW: Survey development was informed by a review of the literature on LDOM pharmacology, safety, and clinical use, with emphasis on pediatric populations. A modified Delphi process was conducted from June 30, 2025, to March 7, 2026. Of 98 clinicians completing a prescreening survey, 51 met eligibility criteria (>10 pediatric patients treated with LDOM) and were invited to participate. Three iterative survey rounds were conducted using REDCap with multidisciplinary input. Consensus was defined as 70% or greater agreement on a 5-point Likert scale. FINDINGS: Of 51 experts, 50 from 9 countries completed rounds 1 and 2, and 49 (98.0% retention rate) completed round 3, reflecting broad international representation. Of 127 initial items considered, 84 achieved consensus. LDOM is supported for pediatric patients (aged ≥4 to <12 years) for hair follicle miniaturization (100%), hair cycle abnormalities (100%), and hair shaft disorders (84%), with adjunctive use in select scarring alopecia (98%). Preference for LDOM over topical minoxidil included concerns for logistical difficulty, poor tolerability, inadequate efficacy, caregiver preference, diffuse hair loss, sensory sensitivities, or risk of toxic effects in domestic animals (pets) (74%-96%). Both fixed weight-based and mg/kg dosing strategies met consensus. Fixed dosing aligned with available tablet formulations (weight <20 kg, 0.250-0.625 mg; 20-40 kg, 1.250 mg; >40 kg, 1.875 mg [ 80%]), while a starting dosage of 0.01 to 0.02 mg/kg/d (73.5%) provided a flexible alternative. Dosage escalation of 50% to 100% and reassessment every 3 to 6 months reached consensus. Contraindications included pericardial effusion or tamponade and pheochromocytoma. For experts, routine baseline testing and blood pressure monitoring were not universally necessary in patients at low risk. LDOM was supported as long-term therapy with tapering strategies, and as combination therapy with additional agents (eg, spironolactone, corticosteroids, Janus kinase inhibitors, and other immunosuppressants) as appropriate for subtype of hair loss. CONCLUSIONS AND RELEVANCE: This international consensus statement provides a structured, pediatric-specific framework for LDOM use, supporting it as a flexible, nonimmunosuppressive therapeutic strategy and addressing key gaps in dosing, safety, and monitoring.
引用
- Akiska YM, Fu J, Castelo-Soccio L, et al. Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders: An International Consensus Statement. JAMA Dermatol. 2026. PMID: 42814435. doi:10.1001/jamadermatol.2026.3749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。